<DOC>
	<DOCNO>NCT01251536</DOCNO>
	<brief_summary>The purpose study determine whether administer escalate dos cetuximab patient early skin toxicity could delay progression disease significant proportion patient study molecular signature response .</brief_summary>
	<brief_title>Cetuximab Standard Dose Escalation First Line Colorectal Cancer</brief_title>
	<detailed_description>Colorectal carcinoma ( CRC ) third common form cancer worldwide remain leading malignancy incidence mortality . In light exist knowledge , investigator propose phase II open label , two arm study patient present K-Ras wild-type metastatic colorectal tumour first line setting . The standard combination irinotecan plus infusional 5-FU/LV ( FOLFIRI ) cetuximab give patient enter study . As investigator hypothesize increase dose cetuximab might increase intensity skin reaction directly correlate outcome , patient experience skin toxicity , dose cetuximab escalate 250 mg/m2 350 mg/m2 500 mg/m2 , order well define effect dose escalation first-line set K-Ras wild type tumour population attempt increase efficacy . Pharmacokinetic study perform document PK parameter cetuximab patient arm select center . Translational research study plan patient . Some depth molecular testing perform subset patient three serial tissue sample accessible metastasis biopsy available .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Written informed consent ( + optional PK TR ) must give accord ICH/GCP national/local regulation . 2 . Patient least 18 year age . 3 . Patient 's body weight â‰¤ 120 kg . 4 . Histologically proven measurable ( RECIST criterion v.1.1 ) metastatic adenocarcinoma colon rectum , previously irradiate area . 5 . KRas wild type tumour eligible treatment cetuximab . 6 . Unresectable metastatic disease . 7 . Life expectancy least 12 week . 8. WHO ECOG performance status : 0 1 . 9 . Effective contraception male female patient risk conception exists . 10 . Adequate organ function . 11 . Adequate bone marrow , hepatic renal function ( assess within 14 day prior study entry ) : Hemoglobin &gt; 10.0 g/dL , absolute neutrophil count &gt; 1.5 x 109/L , platelet count &gt; 100 x 109/L ALAT , ASAT &lt; 2.5 x ULN , &lt; 5 x ULN case liver metastasis Alkaline phosphatase &lt; 2.5 x ULN Total bilirubin &lt; 1.5 x ULN Creatinine clearance &gt; 50 mL/min ( calculate accord Cockroft Gault ) 1 . Prior treatment metastatic disease ( adjuvant therapy fluoropyrimidines +/oxaliplatin base regimen allow stop 6 month prior registration study ) . 2 . Prior treatment EGFR inhibitor chemotherapy irinotecan adjuvant setting . 3 . Surgery ( exclude diagnostic biopsy ) irradiation within 4 week prior study entry . 4 . Administration investigational drug agent/procedure , i.e . participation another trial within 4 week begin treatment . 5 . Concurrent chronic systemic immune therapy , chemotherapy , radiation therapy hormone therapy indicate study protocol . 6 . Any active dermatological condition &gt; grade 1 . 7 . Brain metastasis ( know suspect ) . 8 . Significant impairment intestinal absorption ( e.g . chronic diarrhea , inflammatory bowel disease ) . 9 . Other uncontrolled concomitant illness , include serious uncontrolled intercurrent infection . 10 . Uncontrolled coronary artery disease and/or unstable angina , history myocardial infarction within last 12 month heart failure NYHA class III IV . High risk uncontrolled arrhythmia . 11 . Known allergy adverse reaction drug relate compound . 12 . Known dihydropyrimidine dehydrogenase ( DPD ) deficiency . 13 . Gilbert disease . 14 . Previous ( within 5 year ) concurrent malignancy sit exception surgically cure adequately treat carcinoma insitu cervix basal cell carcinoma skin . 15 . Organ allograft require immunosuppressive therapy . 16 . Pregnancy ( absence confirm serum/urine beta human choriongonadotrophin premenopausal woman ) breastfeed . 17 . Medical , social psychological condition , opinion investigator , would permit patient complete study sign meaningful informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>K-Ras wildtype</keyword>
	<keyword>first line metastatic</keyword>
	<keyword>standard cetuximab + FOLFIRI</keyword>
	<keyword>dose escalation cetuximab</keyword>
</DOC>